



Unlock the Bowel Movement

# Pegovag-C

Polyethylene Glycol, Sodium Chloride, Sodium Bicarbonate  
& Potassium Chloride Concentrate for Oral Solution - 200 ml

La Renon

## Background

- Chronic Constipation (CC) is the most common chronic gastrointestinal symptom. About 30% of the general population experience problems with constipation during their lifetime, with elderly people & women being most affected.<sup>1</sup>
- Polyethylene glycol 3350 + Electrolytes (PEG3350 + E) is widely available worldwide for the treatment of constipation. In 1999, FDA approved PEG 3350 for the treatment of occasional constipation.<sup>2</sup>

## Clinical Evidences


**1. Randomized Clinical Trial :** PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome<sup>3</sup>

No. of Patients : 139 patients  
{PEG 3350 + E (N = 68) or placebo (N = 71)}

Duration : 28 Days

Dose : 1-3 Sachet (13.8 g / Sachet) / day

### Result :




Mean number of spontaneous complete bowel movements (SCBMs) during treatment with either polyethylene glycol 3350 plus electrolytes (PEG 3350 + E) or placebo.

**Conclusions :** PEG 3350 + E is superior to placebo in relieving IBS – C over a 28-day treatment period. Superior efficacy in increasing both SBM & SCBM number was accompanied by a statistically significant reduction in abdominal discomfort/pain during treatment compared with baseline.

\* SBM - Spontaneous Bowel Movement

\* SCBM - Spontaneous Complete Bowel Movement




## 2. Polyethylene glycol 3350 in occasional constipation : A one-week, randomized, placebo-controlled, double-blind trial<sup>4</sup>

No. of Patients : 203 patients  
(PEG 3350=102 & Placebo=101)

Duration : 7 Days

Dose : Placebo or PEG (17g) OD

### Result :



Assessment of primary outcome between polyethylene glycol 3350 & placebo (per protocol population)

**Primary Efficacy Analysis :** 36 subjects (36.7%) on PEG 3350 reported complete resolution compared with 23 (24.5%) receiving placebo ( $P=0.0595$ )

**Secondary Efficacy Analysis :** Subjects using PEG 3350 experienced significant relief in straining & reduction in the hardness of stools over the 7-d treatment period ( $P<0.0001$ ).

**Conclusions :** Oral administration of PEG 3350 is effective, safe & well-tolerated in subjects with occasional constipation.

## Key Benefits of PEG 3350 + Electrolytes in Constipation

- PEG 3350 is a laxative which is metabolically inert & is not degraded by bacteria.<sup>5</sup>
- PEG is not metabolized, the effects of colonic adaptation & hydrogen gas production associated with carbohydrate agents such as mannitol, sorbitol & lactulose are not encountered.<sup>5</sup>
- It increases bowel movement per week, improves stool consistency & reduces the time to the first Bowel Movement.<sup>5</sup>
- PEG 3350 compared with lactulose provided a higher success rate with fewer side effects.<sup>6</sup>
- Electrolytes prevent their loss through the faeces.

## Description

PEGOVAG-C oral solution is a combination medicine used in the treatment of constipation and acts as a laxative that helps to treat constipation (infrequent bowel movements and hard, dry stools).

Each 25 ml of PEGOVAG-C oral solution contains PEG 3350 (13.125 gm), Sodium Chloride (0.3507 gm), Sodium Bicarbonate (0.1785 gm) and Potassium Chloride (0.0466 gm) and is available as a 200 ml oral solution.

## Indication

PEGOVAG-C is indicated for the treatment of constipation.

## Mechanism of Action

**Pharmacotherapeutic Group : Osmotic Laxative**

- PEG 3350 acts by virtue of its osmotic action in the gut, which induces a laxative effect. PEG 3350 increases the stool volume, triggering colon motility via neuromuscular pathways leading to an improved propulsive colonic transportation of the softened stools & facilitation of defecation.
- Electrolytes combined with PEG 3350 are exchanged across the intestinal barrier with serum electrolytes & excreted in faecal water without net gain or loss of sodium, potassium & water.

## Dosage & Administration

The recommended dose of PEGOVAG-C is 25 ml of solution diluted in 100 ml of water, 1-3 times daily in divided doses according to the individual's response or as directed by the Physicians.

## Storage

Store protected from light at a temperature not exceeding 30°C.  
Do Not Refrigerate or freeze.

## Presentation

PEGOVAG-C is available in 200 ml of the bottle.



### References:

1. 10.1186/s12876-015-0366-3, De Giorgio et al. BMC Gastroenterology (2015) | 2. Canadian Journal of Gastroenterology and Hepatology Volume 2022, Article ID 3533504, 8 pages
3. World J Gastrointest Pharmacol Ther 2016 May 6; 7(2): 274-282 | 4. Am J Gastroenterol 2013; 108:1508-1515;2 | 5. The American Journal of Gastroenterology, Vol. 97, No. 7, 2002
6. Gut 2004;53:1590-1594